New hope to tame Chemo's harsh side effects and extend life for advanced lung cancer patients
NCT ID NCT05874401
Summary
This study is testing whether a drug called trilaciclib, given before chemotherapy, helps patients with advanced small cell lung cancer live longer. It also aims to see if it reduces severe side effects like low blood cell counts, which are common with chemotherapy. About 302 patients whose cancer has progressed after initial treatment will receive either trilaciclib or a placebo before their topotecan chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital
RECRUITINGSeville, Spain
Contact
Conditions
Explore the condition pages connected to this study.